Key result
Combination therapy with olmesartan and azelnidipine significantly suppressed aortic atherosclerosis and reactive oxygen species production in diabetic ApoE-/- mice independent of blood pressure lowering.
Why the study?
Does combination therapy with olmesartan and azelnidipine prevent atherosclerosis in diabetic ApoE-/- mice?
Does combination therapy with olmesartan and azelnidipine prevent atherosclerosis in diabetic ApoE-/- mice?
Combination therapy with olmesartan and azelnidipine exerts anti-atherogenic effects in diabetic mice through suppression of oxidative stress and activation of eNOS, independent of blood pressure lowering.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for anti-atherosclerotic effects of olmesartan-azelnidipine in diabetes; human trials required before any clinical consideration.
Many studies have aimed to identify anti-atherogenic agents in cardiovascular medicine. We have recently demonstrated that the combination therapy with olmesartan (OLM), an angiotensin II receptor blocker, and azelnidipine (AZL), a dihydroprydine calcium-channel blocker, improves endothelial function in diabetic Apolipoprotein-deficient (ApoE(-/-)) mice. In the present study, we examined whether this combination therapy also inhibits atherosclerosis in mice. We used male control and streptozocin-induced diabetic ApoE(-/-) mice. Diabetic ApoE(-/-) mice were orally treated for 5 weeks with vehicle (Untreated), OLM (30 mg/kg/day), AZL (10 mg/kg/day), their combination (OLM+AZL), or hydralazine (HYD, 5 mg/kg/day) as an antihypertensive control. At 5 weeks, systolic blood pressure was significantly elevated in Untreated but was normalized in OLM+AZL and HYD. The atherosclerosis area in the thoracic aorta, perivascular fibrosis and medial thickness of the coronary arteries were increased in Untreated and were ameliorated in OLM+AZL but not in HYD. Staining with a fluorescent probe dihydroethidium showed that production of reactive oxygen species was increased in Untreated, and ameliorated in OLM+AZL. Consistent with these findings, macrophage infiltration in the kidney and the expression of receptor for advanced glycation end-products in the heart, kidney and liver were increased in Untreated and were all ameliorated in OLM+AZL, associated with up-regulation of endothelial NO syntheses (eNOS). In conclusion, the combination therapy with OLM and AZL exerts anti-atherogenic effect in diabetic ApoE(-/-) mice through suppression of oxidative stress and activation of eNOS, independent of its blood pressure-lowering effects. Clinically, this combination therapy may be useful for patients with hypertension, hyperlipidemia and diabetes.
No takes yet. Share an insight, caveat, or question.
Noda et al. (2012) studied Atherosclerosis in diabetes (n=36). Olmesartan and Azelnidipine combination vs. Vehicle, OLM alone, AZL alone, or Hydralazine was evaluated on Aortic atherosclerosis area (p=<0.05). Combination therapy with olmesartan and azelnidipine significantly suppressed aortic atherosclerosis and reactive oxygen species production in diabetic ApoE-/- mice independent of blood pressure lowering.
Synapse has enriched 10 related papers. Consider them for comparative context: